{"id":8146,"date":"2025-07-23T22:56:11","date_gmt":"2025-07-23T20:56:11","guid":{"rendered":"https:\/\/rvh-synergie.org\/actualites\/hct-allogenique-faisable-chez-les-patients-ages-atteints-du-syndrome-myelodysplasique\/"},"modified":"2025-07-23T22:56:14","modified_gmt":"2025-07-23T20:56:14","slug":"hct-allogenique-faisable-chez-les-patients-ages-atteints-du-syndrome-myelodysplasique","status":"publish","type":"post","link":"https:\/\/rvh-synergie.org\/actualites\/hct-allogenique-faisable-chez-les-patients-ages-atteints-du-syndrome-myelodysplasique\/","title":{"rendered":"HCT allog\u00e9nique faisable chez les patients \u00e2g\u00e9s atteints du syndrome my\u00e9lodysplasique"},"content":{"rendered":"<div>\n<div class=\"article-gallery lightGallery\">\n<div data-thumb=\"https:\/\/scx1.b-cdn.net\/csz\/news\/tmb\/2022\/cell-1.jpg\" data-src=\"https:\/\/scx2.b-cdn.net\/gfx\/news\/hires\/2022\/cell-1.jpg\" data-sub-html=\"Credit: Pixabay\/CC0 Public Domain\">\n<figure class=\"article-img\">\n<\/figure><\/div>\n<\/div>\n<p>La transplantation allog\u00e9nique des cellules h\u00e9matopo\u00ef\u00e9tiques (allo-HCT) est possible chez les patients plus \u00e2g\u00e9s atteints du syndrome my\u00e9lodysplasique (MDS), selon une \u00e9tude publi\u00e9e en ligne le 26 juin dans le <i>Journal europ\u00e9en d&rsquo;h\u00e9matologie<\/i>.<\/p>\n<p>Fernando Barroso Duarte, Ph.D., de l&rsquo;h\u00f4pital universitaire de Walter Cant\u00eddio \u00e0 Fortaleza, au Br\u00e9sil, et des coll\u00e8gues ont men\u00e9 une \u00e9tude multicentrique r\u00e9trospective pour comparer les r\u00e9sultats et \u00e9valuer les risques associ\u00e9s \u00e0 Allo-HCT chez les patients atteints de MDS de 65 ans et plus \u00e2g\u00e9es contre 2023. inscrit; 16% \u00e9taient \u00e2g\u00e9s de 65 ans et plus.<\/p>\n<p>Les chercheurs ont constat\u00e9 que la survie globale (OS) \u00e9tait de 49,3% et 56,7% chez les patients de 65 ans et plus et de moins de 65 ans, respectivement, \u00e0 cinq ans, et la survie sans progression (PFS) \u00e9tait respectivement de 48,4% et 56,2%. Les taux d&rsquo;incidence cumulative de rechute et de mortalit\u00e9 non rel\u00e2ch\u00e9e \u00e9taient respectivement de 13,6% et 33,8%. Aucune diff\u00e9rence significative n&rsquo;a \u00e9t\u00e9 observ\u00e9e entre les groupes d&rsquo;\u00e2ge dans la SG, la mortalit\u00e9 sans rel\u00e2che ou la PFS apr\u00e8s correspondance de scores de propension. Il y avait une association observ\u00e9e entre la PFS chez les patients \u00e2g\u00e9s de 65 ans et plus avec une stratification du syst\u00e8me de notation pronostique international r\u00e9vis\u00e9 \u00e0 haut risque. Un risque plus \u00e9lev\u00e9 de rechute a \u00e9t\u00e9 observ\u00e9 pour les patients \u00e2g\u00e9s de 65 ans et plus par rapport aux personnes \u00e2g\u00e9es de moins de 65 ans. Le risque de pr\u00e9valence \u00e9tait associ\u00e9 au sexe masculin, \u00e0 un conditionnement de l&rsquo;intensit\u00e9 r\u00e9duite, \u00e0 des cellules sanguines mobilis\u00e9es et \u00e0 un traitement ant\u00e9rieur chez des patients \u00e2g\u00e9s de 65 ans et plus, alors que chez les personnes \u00e2g\u00e9es de moins de 65 ans, des associations ont \u00e9t\u00e9 observ\u00e9es avec des complications et une maladie chronique du greffon contre l&rsquo;h\u00f4te.<\/p>\n<p>\u00ab\u00a0L&rsquo;allo-HCT est possible chez les patients \u00e2g\u00e9s atteints de MDS, sans diff\u00e9rences significatives dans la SG ou le risque de mortalit\u00e9 par rapport aux patients plus jeunes\u00a0\u00bb, \u00e9crivent les auteurs. \u00ab\u00a0Cependant, l&rsquo;\u00e2ge peut influencer la progression de la maladie chez les patients \u00e2g\u00e9s \u00e0 tr\u00e8s haut risque atteints de MDS, ainsi que le risque de rechute apr\u00e8s la transplantation. Nous avons identifi\u00e9 que le sexe masculin, l&rsquo;utilisation d&rsquo;un r\u00e9gime de conditionnement d&rsquo;intensit\u00e9 r\u00e9duit et une greffe de cellules sanguines mobilis\u00e9 sont des facteurs de risque pr\u00e9valants associ\u00e9s aux patients \u00e2g\u00e9s atteints de MDS subissant du HCT.\u00a0\u00bb<\/p>\n<p>                                        <!-- print only --><\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>La transplantation allog\u00e9nique des cellules h\u00e9matopo\u00ef\u00e9tiques (allo-HCT) est possible chez les patients plus \u00e2g\u00e9s atteints<\/p>\n","protected":false},"author":1,"featured_media":8147,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[86],"tags":[1382,6081,282,56,6082,6080,49,2679,616,283],"class_list":["post-8146","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-les-maladies","tag-ages","tag-allogenique","tag-atteints","tag-chez","tag-faisable","tag-hct","tag-les","tag-myelodysplasique","tag-patients","tag-syndrome","generate-columns","tablet-grid-50","mobile-grid-100","grid-parent","grid-50","resize-featured-image"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>HCT allog\u00e9nique faisable chez les patients \u00e2g\u00e9s atteints du syndrome my\u00e9lodysplasique - RVH-Synergie.org<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/rvh-synergie.org\/actualites\/hct-allogenique-faisable-chez-les-patients-ages-atteints-du-syndrome-myelodysplasique\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HCT allog\u00e9nique faisable chez les patients \u00e2g\u00e9s atteints du syndrome my\u00e9lodysplasique - RVH-Synergie.org\" \/>\n<meta property=\"og:description\" content=\"La transplantation allog\u00e9nique des cellules h\u00e9matopo\u00ef\u00e9tiques (allo-HCT) est possible chez les patients plus \u00e2g\u00e9s atteints\" \/>\n<meta property=\"og:url\" content=\"https:\/\/rvh-synergie.org\/actualites\/hct-allogenique-faisable-chez-les-patients-ages-atteints-du-syndrome-myelodysplasique\/\" \/>\n<meta property=\"og:site_name\" content=\"RVH-Synergie\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-23T20:56:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-23T20:56:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/07\/1753304172_HCT-allogenique-faisable-chez-les-patients-ages-atteints-du-syndrome.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Charles Martinez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Charles Martinez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/hct-allogenique-faisable-chez-les-patients-ages-atteints-du-syndrome-myelodysplasique\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/hct-allogenique-faisable-chez-les-patients-ages-atteints-du-syndrome-myelodysplasique\/\"},\"author\":{\"name\":\"Charles Martinez\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560\"},\"headline\":\"HCT allog\u00e9nique faisable chez les patients \u00e2g\u00e9s atteints du syndrome my\u00e9lodysplasique\",\"datePublished\":\"2025-07-23T20:56:11+00:00\",\"dateModified\":\"2025-07-23T20:56:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/hct-allogenique-faisable-chez-les-patients-ages-atteints-du-syndrome-myelodysplasique\/\"},\"wordCount\":441,\"publisher\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/hct-allogenique-faisable-chez-les-patients-ages-atteints-du-syndrome-myelodysplasique\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/07\/1753304172_HCT-allogenique-faisable-chez-les-patients-ages-atteints-du-syndrome.jpg\",\"keywords\":[\"\u00e2g\u00e9s\",\"allog\u00e9nique\",\"atteints\",\"chez\",\"faisable\",\"HCT\",\"Les\",\"my\u00e9lodysplasique\",\"patients\",\"syndrome\"],\"articleSection\":[\"Les maladies\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/hct-allogenique-faisable-chez-les-patients-ages-atteints-du-syndrome-myelodysplasique\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/hct-allogenique-faisable-chez-les-patients-ages-atteints-du-syndrome-myelodysplasique\/\",\"name\":\"HCT allog\u00e9nique faisable chez les patients \u00e2g\u00e9s atteints du syndrome my\u00e9lodysplasique - RVH-Synergie.org\",\"isPartOf\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/hct-allogenique-faisable-chez-les-patients-ages-atteints-du-syndrome-myelodysplasique\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/hct-allogenique-faisable-chez-les-patients-ages-atteints-du-syndrome-myelodysplasique\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/07\/1753304172_HCT-allogenique-faisable-chez-les-patients-ages-atteints-du-syndrome.jpg\",\"datePublished\":\"2025-07-23T20:56:11+00:00\",\"dateModified\":\"2025-07-23T20:56:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/hct-allogenique-faisable-chez-les-patients-ages-atteints-du-syndrome-myelodysplasique\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/rvh-synergie.org\/actualites\/hct-allogenique-faisable-chez-les-patients-ages-atteints-du-syndrome-myelodysplasique\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/hct-allogenique-faisable-chez-les-patients-ages-atteints-du-syndrome-myelodysplasique\/#primaryimage\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/07\/1753304172_HCT-allogenique-faisable-chez-les-patients-ages-atteints-du-syndrome.jpg\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/07\/1753304172_HCT-allogenique-faisable-chez-les-patients-ages-atteints-du-syndrome.jpg\",\"width\":1920,\"height\":960,\"caption\":\"HCT allog\u00e9nique faisable chez les patients \u00e2g\u00e9s atteints du syndrome my\u00e9lodysplasique\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/hct-allogenique-faisable-chez-les-patients-ages-atteints-du-syndrome-myelodysplasique\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/rvh-synergie.org\/actualites\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HCT allog\u00e9nique faisable chez les patients \u00e2g\u00e9s atteints du syndrome my\u00e9lodysplasique\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#website\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/\",\"name\":\"RVH-Synergie.org\",\"description\":\"RVH-Synergie, site ind\u00e9pendant d&#039;informations sur la prise en charge des addictions.\",\"publisher\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/rvh-synergie.org\/actualites\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\",\"name\":\"RVH-Synergie.org\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png\",\"width\":512,\"height\":512,\"caption\":\"RVH-Synergie.org\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560\",\"name\":\"Charles Martinez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg\",\"caption\":\"Charles Martinez\"},\"description\":\"Bonjour, je m'appelle Charles Martinez, r\u00e9dacteur passionn\u00e9 pour le m\u00e9dia RVH-synergie.org, d\u00e9di\u00e9 aux addictions et aux maladies. Depuis plus de dix ans, j'explore et rapporte les histoires poignantes des individus confront\u00e9s \u00e0 ces d\u00e9fis, tout en sensibilisant le public aux traitements novateurs et aux progr\u00e8s scientifiques dans ce domaine. Mon engagement r\u00e9side dans l'espoir de cr\u00e9er une communaut\u00e9 inform\u00e9e et empathique, pr\u00eate \u00e0 soutenir ceux qui luttent contre ces \u00e9preuves.\",\"sameAs\":[\"https:\/\/rvh-synergie.org\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HCT allog\u00e9nique faisable chez les patients \u00e2g\u00e9s atteints du syndrome my\u00e9lodysplasique - RVH-Synergie.org","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/rvh-synergie.org\/actualites\/hct-allogenique-faisable-chez-les-patients-ages-atteints-du-syndrome-myelodysplasique\/","og_locale":"fr_FR","og_type":"article","og_title":"HCT allog\u00e9nique faisable chez les patients \u00e2g\u00e9s atteints du syndrome my\u00e9lodysplasique - RVH-Synergie.org","og_description":"La transplantation allog\u00e9nique des cellules h\u00e9matopo\u00ef\u00e9tiques (allo-HCT) est possible chez les patients plus \u00e2g\u00e9s atteints","og_url":"https:\/\/rvh-synergie.org\/actualites\/hct-allogenique-faisable-chez-les-patients-ages-atteints-du-syndrome-myelodysplasique\/","og_site_name":"RVH-Synergie","article_published_time":"2025-07-23T20:56:11+00:00","article_modified_time":"2025-07-23T20:56:14+00:00","og_image":[{"width":1920,"height":960,"url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/07\/1753304172_HCT-allogenique-faisable-chez-les-patients-ages-atteints-du-syndrome.jpg","type":"image\/jpeg"}],"author":"Charles Martinez","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Charles Martinez","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/rvh-synergie.org\/actualites\/hct-allogenique-faisable-chez-les-patients-ages-atteints-du-syndrome-myelodysplasique\/#article","isPartOf":{"@id":"https:\/\/rvh-synergie.org\/actualites\/hct-allogenique-faisable-chez-les-patients-ages-atteints-du-syndrome-myelodysplasique\/"},"author":{"name":"Charles Martinez","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560"},"headline":"HCT allog\u00e9nique faisable chez les patients \u00e2g\u00e9s atteints du syndrome my\u00e9lodysplasique","datePublished":"2025-07-23T20:56:11+00:00","dateModified":"2025-07-23T20:56:14+00:00","mainEntityOfPage":{"@id":"https:\/\/rvh-synergie.org\/actualites\/hct-allogenique-faisable-chez-les-patients-ages-atteints-du-syndrome-myelodysplasique\/"},"wordCount":441,"publisher":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#organization"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/hct-allogenique-faisable-chez-les-patients-ages-atteints-du-syndrome-myelodysplasique\/#primaryimage"},"thumbnailUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/07\/1753304172_HCT-allogenique-faisable-chez-les-patients-ages-atteints-du-syndrome.jpg","keywords":["\u00e2g\u00e9s","allog\u00e9nique","atteints","chez","faisable","HCT","Les","my\u00e9lodysplasique","patients","syndrome"],"articleSection":["Les maladies"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/rvh-synergie.org\/actualites\/hct-allogenique-faisable-chez-les-patients-ages-atteints-du-syndrome-myelodysplasique\/","url":"https:\/\/rvh-synergie.org\/actualites\/hct-allogenique-faisable-chez-les-patients-ages-atteints-du-syndrome-myelodysplasique\/","name":"HCT allog\u00e9nique faisable chez les patients \u00e2g\u00e9s atteints du syndrome my\u00e9lodysplasique - RVH-Synergie.org","isPartOf":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#website"},"primaryImageOfPage":{"@id":"https:\/\/rvh-synergie.org\/actualites\/hct-allogenique-faisable-chez-les-patients-ages-atteints-du-syndrome-myelodysplasique\/#primaryimage"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/hct-allogenique-faisable-chez-les-patients-ages-atteints-du-syndrome-myelodysplasique\/#primaryimage"},"thumbnailUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/07\/1753304172_HCT-allogenique-faisable-chez-les-patients-ages-atteints-du-syndrome.jpg","datePublished":"2025-07-23T20:56:11+00:00","dateModified":"2025-07-23T20:56:14+00:00","breadcrumb":{"@id":"https:\/\/rvh-synergie.org\/actualites\/hct-allogenique-faisable-chez-les-patients-ages-atteints-du-syndrome-myelodysplasique\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/rvh-synergie.org\/actualites\/hct-allogenique-faisable-chez-les-patients-ages-atteints-du-syndrome-myelodysplasique\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/hct-allogenique-faisable-chez-les-patients-ages-atteints-du-syndrome-myelodysplasique\/#primaryimage","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/07\/1753304172_HCT-allogenique-faisable-chez-les-patients-ages-atteints-du-syndrome.jpg","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/07\/1753304172_HCT-allogenique-faisable-chez-les-patients-ages-atteints-du-syndrome.jpg","width":1920,"height":960,"caption":"HCT allog\u00e9nique faisable chez les patients \u00e2g\u00e9s atteints du syndrome my\u00e9lodysplasique"},{"@type":"BreadcrumbList","@id":"https:\/\/rvh-synergie.org\/actualites\/hct-allogenique-faisable-chez-les-patients-ages-atteints-du-syndrome-myelodysplasique\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/rvh-synergie.org\/actualites\/"},{"@type":"ListItem","position":2,"name":"HCT allog\u00e9nique faisable chez les patients \u00e2g\u00e9s atteints du syndrome my\u00e9lodysplasique"}]},{"@type":"WebSite","@id":"https:\/\/rvh-synergie.org\/actualites\/#website","url":"https:\/\/rvh-synergie.org\/actualites\/","name":"RVH-Synergie.org","description":"RVH-Synergie, site ind\u00e9pendant d&#039;informations sur la prise en charge des addictions.","publisher":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/rvh-synergie.org\/actualites\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/rvh-synergie.org\/actualites\/#organization","name":"RVH-Synergie.org","url":"https:\/\/rvh-synergie.org\/actualites\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png","width":512,"height":512,"caption":"RVH-Synergie.org"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560","name":"Charles Martinez","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/image\/","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg","caption":"Charles Martinez"},"description":"Bonjour, je m'appelle Charles Martinez, r\u00e9dacteur passionn\u00e9 pour le m\u00e9dia RVH-synergie.org, d\u00e9di\u00e9 aux addictions et aux maladies. Depuis plus de dix ans, j'explore et rapporte les histoires poignantes des individus confront\u00e9s \u00e0 ces d\u00e9fis, tout en sensibilisant le public aux traitements novateurs et aux progr\u00e8s scientifiques dans ce domaine. Mon engagement r\u00e9side dans l'espoir de cr\u00e9er une communaut\u00e9 inform\u00e9e et empathique, pr\u00eate \u00e0 soutenir ceux qui luttent contre ces \u00e9preuves.","sameAs":["https:\/\/rvh-synergie.org\/"]}]}},"_links":{"self":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts\/8146","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/comments?post=8146"}],"version-history":[{"count":0,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts\/8146\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/media\/8147"}],"wp:attachment":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/media?parent=8146"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/categories?post=8146"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/tags?post=8146"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}